Renalytix Reports Full Year Fiscal 2022 Results
Renalytix announced its full year results for the twelve months ended 30 June 2022.
KidneyIntelX Medicare Update
Renalytix announced that the Federal Medicare Administrative Contractor (MAC) National Government Services (NGS) has initiated payment of claims for KidneyIntelX testing for patients with Medicare coverage.
KidneyIntelX Clinical Utility and Health Economics Validated in Multiple Data Releases at American Society of Nephrology
Four presentations, including first clinical utility findings from multi-year real world evidence results from a major healthcare system underscore value of KidneyIntelX™ platform in improving cost economics for Medicare population.
Data Results Published in American Journal of Managed Care demonstrate adoption and clinical utility of KidneyIntelXTM with Primary Care Physicians
98% of 401 Primary Care Physicians confirmed KidneyIntelX has value as a risk decision tool in their adult patients with type 2 diabetes and chronic kidney disease stages 1-3b.
KidneyIntelX™ Demonstrates Ability to Assess Risk of Heart Failure Hospitalization and Death in Large International Diabetic Kidney Disease Patient Cohort
Data shared in oral presentation at American Diabetes Association 82nd Scientific Sessions® and published in Kidney360 highlights importance in early understanding of cardiovascular risk, a leading cause of death in patients with diabetes and chronic kidney disease
Renalytix plc successful completion of $30.0 million financing package
Renalytix announced the successful completion of $30.0 million financing package
Renalytix Reaches Enrollment Milestone for Building KidneyIntelX as Premier Precision Medicine Platform for Kidney Disease and Diabetes
Renalytix Reaches Enrollment Milestone for Building KidneyIntelX as Premier Precision Medicine Platform for Kidney Disease and Diabetes
Confirmation of Appointment of Timothy Scannell to Renalytix Board of Directors
Confirmation of Appointment of Timothy Scannell to Renalytix Board of Directors
Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2022
Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2022
Renalytix Launches myIntelX, Providing National Physician Access to KidneyIntelX Testing Platform
myIntelX will be launching in conjunction with KidneyIntelX going live at Atrium Health, and will expand testing services across all Renalytix healthcare provider partners
Renalytix to Appoint Timothy Scannell to Board of Directors
Renalytix announced its intention to appoint Timothy Scannell to its board of directors as an independent non-executive director.
Positive Study Results Published for KidneyIntelXTM in Monitoring Patient Response to New Drug Therapy
Positive Study Results Published for KidneyIntelXTM in Monitoring Patient Response to New Drug Therapy
